高增殖的癌细胞作为肺腺癌的新型预后生物标志物起作用,对IA阶段的风险分层特别有用
Yanlu Xiong1,2,3, Yongfu Ma1, Jie Lei2
1Department of Thoracic Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
BMC cancer
|January 8, 2025
概括
肺腺癌 (LUAD) 中的高增殖癌细胞 (HPC) 是一种新的预后因素,特别是在IA阶段的患者中. 这一发现完善了风险分层,以获得更好的精准医学结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 肺腺癌 (LUAD) 风险分层需要改进,特别是在I.A阶段.
- 目前的分期缺乏对早期LUAD患者的全面分子洞察力.
研究的目的:
- 为了分子分层的LUAD患者,专注于阶段IA.
- 在LUAD中识别和描述高度增殖的癌细胞 (HPC).
主要方法:
- 单细胞RNA测序 (scRNA-seq),免疫组织化学 (IHC) 和流细胞测量被用来识别和量化HPCs.
- 基因组丰富分析量化了LUAD数据集中的HPC含量.
- 使用HPC相关基因开发了一个预后预测模型 (HSurADs R包).
主要成果:
- 在LUAD组织中,很少有HPC表现出恶性扩散和微环境相互作用.
- 高HPC含量是LUAD中整体存活率 (OS) 的独立风险因素,包括阶段IA.
- HPC水平与病理进展相关,并可能受到TP53突变的影响,从而使IA预后更精细.
结论:
- HPC 含量作为 LUAD 的新生预后生物标志物.
- HPC量化为IA阶段的LUAD患者提供了更好的风险分层.
- 在HSurADs R包提供了一个工具,用于临床预后预测在LUAD.
更多相关视频
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.6K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K